Trial Profile
A Phase I, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of TAS-115 in Patients with Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2022
Price :
$35
*
At a glance
- Drugs Pamufetinib (Primary)
- Indications Osteosarcoma; Solid tumours
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 01 Feb 2022 Planned End Date changed from 31 Dec 2019 to 31 Dec 2022.
- 12 Jun 2021 Results (at data cut-off 19 Aug 2018; n=20) assessing efficacy and safety of TAS-115 in expansion cohort in osteosarcoma patients, published in the Investigational New Drugs.
- 10 Dec 2019 Results (n=67; at data cut-off: 19 August 2018) assessing safety, tolerability, pharmacokinetics of TAS-115 in patients with advanced solid tumors, published in the Investigational New Drugs.